Cannabis which is commonly referred as marijuana, is the commonly used illicit drug. Marijuana has been used for the past thousands of years, largely for two purposes, for medicinal purpose and also for getting high. The people can smoke marijuana, drink it in a tea or eat in the various products such as brownies or chocolate bar.
Few people also use medical cannabis to treat anorexia, chronic pain, nausea, muscle spasticity, and sleep disturbances. Most of the countries have banned the use of marijuana.
Cannabis is legalised only in few countries such as Australia, Canada, Uruguay, Spain, Luxembourg, Peru, New Zealand and District of Columbia in the United States.
While the federal law of the United States still prohibits the sale and use of marijuana, hemp was legalised at the national level in the last year of December 2018.
Cannabis stocks are in great demand right now. Few have projected that the annual Global cannabis market could be worth approximately $150 billion in the next 15 years.
S&P Index Performance
On 18 December 2019, the S&P/ASX 200 Healthcare sector was last traded at 41,131.88 points, with a rise of 0.88 per cent compared to the previous close. The S&P/ASX 200 Index last traded at 6851.40 points, up by 0.06 per cent from its previous close
Let us discuss a stock from Cannabis space who has recently launched its IPO
Emerald Clinics, founded by medical innovators, is a healthcare technology and services company. The first patient that the company attended to was in December 2018. Emerald’s team includes experienced physicians and experts in clinical trial to deliver world class patient care. The company plans to expand its existing clinics in Perth, Sydney, Melbourne and regional NSW with further clinics in 2020.
The Emerald Care Model
The company has a clinical care team focussed on research. The patients who are referred to the company are followed-up from time to time and are invited to complete their healthcare assessments. The data generated from these assessments helps the company to manage the individual patient optimally.
The Emerald Data Platform
To capture and aggregate anonymous clinical data from every consenting patient, the company uses different healthcare technologies. The data helps the team to cater to the patient more effectively.
The industry in which the company operates is subject to international and domestic competition. The company has undertaken all the required due diligence in its operations and business decisions but has no influence or control over the activities or actions of its competitors and their actions may impact the financial performance of the company.
Growth & Expansion Plans
The growth and expansion plans for the company depends upon the number of factors such as its services and product offerings. If the company fails to implement an expansion plan, the financial performance is likely to be negatively affected. The company’s financial performance is affected mainly by demand for medicinal cannabis products and relevant care in Australia.
Reliance on Key Personnel and experienced Clinicians
The company is highly dependent on the management and its key personnel, including the experienced clinicians. If one or more of these key persons cease to be part of the team, it could have a negative impact on the financial performance of the company. The highly qualified and capable staff members are very important for the success of the company.
Emerald Clinics launched Initial Public offering (IPO)
On 11 December 2019, the company has launched the prospectus for an IPO with the Australian Securities and Investments Commission (ASIC) to offer approximately 40 million of fully paid ordinary shares at an issue price of $0.20 per share to raise around $8 million.
The Prospectus also includes the offer of up to 20,625,000 shares to be issued on conversion of the Convertible Notes. It is anticipated that the IPO and the convertible note offer will close on 17 January 2020 at 5.00 PM. The company’s directors reserve the right to close the offer at any time and extend the date without any prior notice.
The company’s Board believes that the initial public offer gives an attractive opportunity to investors become the company’s shareholder, a company which possesses data-driven cannabinoid-based medicines and a large number of clinics.
Minimum and Maximum Subscription
Under the public offer, the minimum subscription is $6 million or 30 million shares. The maximum subscription that the company may raise under the IPO is $8 million through the issue of 40 million shares.
Use of Proceeds
The proceed raised under the public will allow the company to:
- Expand the number of clinics in Australia
- Attract and retain the clinical staff
- Developing the novel IP for the use of cannabinoid medicine
- Commercialise and development of the data platform
- To meet the offer costs and conditions to apply for official quotation of the shares on the ASX
Lead Manager for the IPO
PAC Partners has been appointed by the company as a lead manager of the public offer. The company has agreed to pay the PAC Partner, a capital raising and selling fee of 6 per cent of the total amount raised under the offer.
The company also pays the lead manager and its associates:
- 140,000 shares at an issue price of $0.10 each as a part of seed raising.
- Emerald Clinics has agreed to pay the lead manager 1,00,000 shares at a nominal issue price of $0.0001 each.
- $183,000 for services provides in connection to the seed capital raising for the company, conducted in 2018.
- $168,000 for service provided for the issue of convertible notes.
- The PAC Partner and its associates have an interest in 2,140,000 Shares or 1.16 per cent of the company’s equity as on the date of lodgement of the prospectus.
Post seven days from the date of prospectus, the company can apply to Australian Stock Exchange for the official listing of its shares. If the Australian stock exchange does not grant permission for official listing within the three months after the date of prospectus, then none of the shares on offer would be issued and allotted.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
There is no one left untouched by the charm of the multibillion-dollar global boom in cannabis. Its glorious journey from a criminalized drug to being used in over 20 countries for treating medical conditions.
No wonder the cannabis stocks are on the edge of a green rush. Don’t miss out on the happenings in the cannabis sector and take advantage of the growth phase of this sector by subscribing to our report on Marijuana stocks in Australia.
Find out the drivers for the rise in cannabis stock rates Even though the cannabis sector is in its growing phase, Australian cannabis stocks have already started to rise actively due to a hastily increasing patient base, and a legislative landscape that is gradually beginning to liberalise.
Outreach and future of cannabis stocks As countries liberalise regulation for medical and recreational use of cannabis, it is predicted that the industry would grow sharply in upcoming years The global cannabis market stands currently at around $8 billion and it is expected that the hemp derived CBD market to hit approximately $22 billion by 2022.
Key Players in the sector Althea Group Holdings Limited (ASX: AGH) and Cann Group Limited (ASX: CAN) are amongst the top players. Other Australia cannabis market players are- MGC Pharmaceuticals Ltd (ASX: MXC), Elixinol Global Limited (ASX: EXL), THC Global Group Limited (ASX: THC), AusCann Group Holdings Limited (ASX: AC8)